Gideon Capital Advisors’s Juno Therapeutics, Inc. JUNO Stock Holding History

Gideon Capital Advisors’s Portfolio JUNO Stock Details JUNO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-4,716	Closed	-$216K	–	518
2017 Q4	$216K	Buy	+4,716	New	+$235K	0.19%	256

Other funds holding JUNO

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM

Gideon Capital Advisors's JUNO Position: Q1 2018 in Review

Gideon Capital Advisors sold out of Juno Therapeutics, Inc. (JUNO) in Q1 2018, closing a stake of 4,716 shares — an estimated $216K sold.

Gideon Capital Advisors first reported a position in JUNO in Q4 2017 and held it in 1 quarter. The position peaked at $216K in Q4 2017. 2 funds tracked by Wall St. Rank hold JUNO as of Q1 2018.

Gideon Capital Advisors reported no remaining Juno Therapeutics, Inc. position as of Q1 2018 after selling out during the quarter.
Gideon Capital Advisors sold 4,716 Juno Therapeutics, Inc. shares in Q1 2018, an estimated $216K.
Gideon Capital Advisors first reported a position in Juno Therapeutics, Inc. in Q4 2017 and held it in 1 quarter.
Gideon Capital Advisors's Juno Therapeutics, Inc. position peaked at $216K in Q4 2017.
2 funds tracked by Wall St. Rank held Juno Therapeutics, Inc. as of Q1 2018.

Based on Gideon Capital Advisors's 13F filing for Q1 2018, filed 14 May 2018.